AstraZeneca sales fall on generic competition; Anthem broadens access for Duchenne muscular dystrophy drug; researchers are developing new biopsy techniques
How Aubagio became the most switched-to oral MS drug
Second to market and dismissed as inferior to the competition, Sanofi’s Aubagio seemed destined for lower-tier status. Here’s how it overcame the initial obstacles and, five years later, become a potent market force
Five things for pharma marketers to know: Friday, August 18, 2017
Opdivo/Yervoy combination shows improved survival for melanoma patients in trial; global immunotherapy market likely to reach $75 billion by 2022; Mylan expands EpiPen recall
Five things for pharma marketers to know: Tuesday, January 17, 2017